GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus

GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus New York, NY, June 23, 2022 (GLOBE NEWSWIRE) – GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that the Company and the University of Newcastle in Australia […]

GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse

GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse Intelligent Fingerprinting Limited’s commercial-stage, revenue-generating platform technology would provide an expanded product upon which to leverage the existing GBS pipeline New York, NY, June 16, 2022 (GLOBE NEWSWIRE) – GBS Inc. (Nasdaq: […]

GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights

GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights Initiated prospective study to collect coincident samples of oral fluid and blood following IRB approval. Finalizing site selection at the University of Newcastle campus for the high-tech manufacturing and production facility. $10.76 Million in Cash, Cash Equivalents, and Marketable Securities as of March […]

GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center

GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center The trial is single center, prospective study to collect coincident samples of oral fluid and blood to evaluate the time-course of glucose.Trial is expected to enroll approximately 40 adult subjects diagnosed with type 2 diabetes.GBS is seeking to […]

GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study

GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study New York, NY, November 30, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it will commence preparation for clinical trials of its rapid SARS-CoV-2 Antibody […]

GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights

GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights Clinical Validation Study Results for SARS CoV2 Ab Test.Evaluating site locations for build out of high-tech manufacturing facility supported by $4.7 Million Grant Funding from Australian Government.$12.6 Million in Cash, Cash Equivalents, and Marketable Securities as of September 30, 2021, Provides Estimated Runway […]

GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights

GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights Awarded $4.7 Million Government Grant Funding to support the building of a high-tech manufacturing facility.Signs Strategic Partnerships with Johns Hopkins University, Wyss Institute from Harvard University, University of Newcastle and Precision Medical Architects.$12.7 Million in Cash, Cash Equivalents, and […]

GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test

GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test New York, NY, July 26, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced L.E.K. Consulting Hong Kong Pty […]

GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology

GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology New York, NY, July 8, 2021 – GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it has been awarded a USD $4.7 million, Australian Federal Government scientific […]